Lately, PPARα agonists have been proposed as a novel disease-modifying target for sleep-related hypermotor epilepsy (SHE), formerly referred to as nocturnal frontal lobe epilepsy (NFLE), idiopathic epilepsy with an autosomal inherited component, based on the effectiveness of fenofibrate in an NFLE mouse model and as an adjunctive therapy in pharmacoresistant NFLE patients [120]. This evidence concerns the gene PPARA and familial sleep-related hypermotor epilepsy.